KRAS G12A
Clinical trials for KRAS G12A explained in plain language.
Never miss a new study
Get alerted when new KRAS G12A trials appear
Sign up with your email to follow new studies for KRAS G12A, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New immunotherapy option for High-Risk pancreatic cancer patients
Disease control AVAILABLEThis expanded access program offers ELI-002 7P immunotherapy to patients with pancreatic cancer that has specific KRAS or NRAS gene mutations and who are at high risk of the cancer returning after surgery. The treatment aims to stimulate the immune system to fight any remaining c…
Matched conditions: KRAS G12A
Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated May 17, 2026 02:02 UTC
-
New pill targets hard-to-treat cancers with KRAS and BRAF mutations
Disease control Recruiting nowThis early-phase study tests an oral drug called S241656 in adults with advanced cancers that have certain gene changes (KRAS, BRAF, and others). The drug is given alone or with other cancer treatments. The goal is to find safe doses and see if the drug shrinks tumors. About 554 …
Matched conditions: KRAS G12A
Phase: PHASE1, PHASE2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated May 12, 2026 13:40 UTC
-
New pill takes on hard-to-treat KRAS cancers in first human trial
Disease control Recruiting nowThis early-phase study tests a new drug called BBO-11818 in adults with advanced lung, pancreatic, or colorectal cancers that have a KRAS mutation. The main goals are to check safety and find the best dose, while also seeing if the drug can shrink tumors. About 387 participants w…
Matched conditions: KRAS G12A
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated May 07, 2026 18:41 UTC